KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the grant of an inducement award to the Company’s recently appointed Chief Commercial Officer, Nicole Sweeny. In connection with Ms. Sweeny’s appointment, the compensation committee of KalVista’s board of directors granted inducement options to purchase an aggregate of 100,000 shares of KalVista common stock on July 24, 2023 as an inducement material to Ms. Sweeny entering into employment with KalVista. The options have an exercise price of $9.51 per share, which was equal to the closing price of KalVista common stock on the grant date. One-fourth of the options vest on the one-year anniversary of the vesting commencement date and the remainder vest in equal monthly installments over the next three years, in each case subject to Ms. Sweeny’s continued service with the company. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Amended and Restated 2021 Equity Inducement Plan and a stock option agreement covering the grant.

Additionally, on August 1, 2023, the Committee granted one newly-hired employee inducement options to purchase an aggregate of 1,000 shares of KalVista common stock as an inducement material to such employee entering into employment with KalVista. The options have an exercise price of $10.66 per share, which was equal to the closing price of KalVista common stock on the grant date. The vesting details of these options match those of Ms. Sweeny’s award mentioned above. Each stock option has a 10-year term and is subject to the terms and conditions of KalVista’s Amended and Restated 2021 Equity Inducement Plan and a stock option agreement covering the grant.

Both grants were made in accordance with Nasdaq Listing Rule 5635(c)(4).

About KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors for diseases with significant unmet need. KalVista is developing sebetralstat as an oral on-demand therapy for HAE attacks and has achieved its enrollment target for the phase 3 KONFIDENT clinical trial. In addition, KalVista’s oral Factor XIIa inhibitor program represents a new generation of therapies that may further improve the treatment for people living with HAE and other diseases.

For more information about KalVista, please visit www.kalvista.com

For more information on the sebetralstat HAE on-demand Phase 3 KONFIDENT study, please visit www.konfidentstudy.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20230802710635/en/